(Q43576840)

24 November 2017

Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe (English)

1 reference

24 November 2017

1 reference

J Amchin

1

1 reference

24 November 2017

L Ereshefsky

2

1 reference

24 November 2017

W Zarycranski

3

1 reference

24 November 2017

K Taylor

4

1 reference

24 November 2017

D Albano

5

1 reference

24 November 2017

P M Klockowski

6

1 reference

24 November 2017

1 April 2001

1 reference

The Journal of Clinical Pharmacology

24 November 2017

1 reference

24 November 2017

41

1 reference

24 November 2017

443-451

1 reference

24 November 2017

4

1 reference

Antidepressants and drug-metabolizing enzymes--expert group report

24 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Drug-drug interactions involving antidepressants: focus on venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Newer antidepressants and the cytochrome P450 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Determination of dextromethorphan metabolizer phenotype in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Fluoxetine kinetics and protein binding in normal and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010159

10.1177/00912700122010159

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference